Characterizing rare conformational states in drug targets
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
233
NCT06993844
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Phase: Phase 1/2
Role: Lead Sponsor
Start: Jun 10, 2025
Completion: Dec 30, 2027
Loading map...